Last updated: July 27, 2026
Executive summary
Array BioPharma Inc. v. Sandoz Inc., 1:22-cv-01316 (D. Del.) is a patent infringement dispute tied to Array’s oncology product portfolio and the asserted infringement theories in the complaint. A complete litigation summary (asserted patents, claim construction positions, motion history, schedule, and key holdings) cannot be produced from the information available in this record.
What is the Array BioPharma v. Sandoz 1:22-cv-01316 case about?
Answer: The docket identifier 1:22-cv-01316 confirms the case, but the underlying dispute scope is not specified here. A litigation summary requires the asserted patent numbers, the accused product(s), and the specific infringement claims pleaded in the complaint and amended complaints.
Which product and active ingredient is accused in 1:22-cv-01316?
Answer: Not provided in the available information.
Which patents are asserted by Array BioPharma?
Answer: Not provided in the available information.
What patents protect Array BioPharma’s product(s) involved in this dispute?
Answer: Not provided in the available information.
How many patents are asserted in the complaint?
Answer: Not provided in the available information.
Are the asserted patents method-of-use, formulation, or manufacturing patents?
Answer: Not provided in the available information.
What is the procedural posture for Array BioPharma Inc. v. Sandoz Inc. (1:22-cv-01316)?
Answer: Not provided in the available information.
Has the court issued any claim construction or Markman orders?
Answer: Not provided in the available information.
What dispositive motions are pending or decided (summary judgment, motions to dismiss)?
Answer: Not provided in the available information.
What is the trial date and upcoming deadlines?
Answer: Not provided in the available information.
What is the litigation timeline for the case (filing, amendments, key rulings, settlement)?
Answer: Not provided in the available information.
When did the case start and when was it served?
Answer: Not provided in the available information.
Was there a Paragraph IV or biosimilar-style trigger tied to FDA filings?
Answer: Not provided in the available information.
How strong is Array BioPharma’s patent estate in this case?
Answer: Not provided in the available information.
What infringement theories has Array pleaded (literal infringement, doctrine of equivalents)?
Answer: Not provided in the available information.
What invalidity defenses does Sandoz typically raise, and have they been briefed here?
Answer: Not provided in the available information.
What is Sandoz’s defense strategy in Array v. Sandoz (1:22-cv-01316)?
Answer: Not provided in the available information.
Does Sandoz argue non-infringement, invalidity, or both?
Answer: Not provided in the available information.
Has Sandoz moved for exclusion, stayed proceedings, or sought PTAB-related relief?
Answer: Not provided in the available information.
How does this dispute affect generic or biosimilar market entry risk?
Answer: Not provided in the available information.
Does the case look like an ANDA/P-IV teed-up suit or another FDA pathway linkage?
Answer: Not provided in the available information.
What settlements or consent judgments exist for 1:22-cv-01316?
Answer: Not provided in the available information.
If settled, what is the scope (licensed patents, design-arounds, timing)?
Answer: Not provided in the available information.
Key Takeaways
No litigation summary or analysis can be generated from the information currently available: asserted patents, accused product(s), claim scope, motion outcomes, and any settlement terms are not included in the provided record.
FAQs
- What court and district handles Array BioPharma Inc. v. Sandoz Inc. 1:22-cv-01316?
- Which patents does Array assert in 1:22-cv-01316?
- What FDA submission is linked to the litigation in 1:22-cv-01316?
- Has the court issued claim construction in this case?
- Does 1:22-cv-01316 include a settlement agreement or stipulated dismissal?
References
(No sources cited.)
